NOVARTIS PHARMA GmbH
- Pharmaceutical Sales 2007
-
Worldwide: 24,025 million US $
In Germany: 2.8 billion Euro (Novartis Group)
- Product Range
-
The range of therapeutic areas includes: cardiovascular diseases, rheumatic diseases, irritable bowel syndrome, diabetes, cancer, bone diseases, diseases of the central nervous system, immunology, dermatology, asthma, ophthalmics, endocrinology and transplantation
- Key Research Areas
-
Novartis' research and development spans therapeutic areas including: cardiovascular diseases; metabolism/endocrinology; arthritis/inflammation; bone metabolism; oncology; neurology/psychiatry; dermatology; transplantation/immunology and respiratory diseases.
New approaches to selecting potential targets for medicines, including broad in-vitro biological profiling of compounds will increase the number and quality of early therapeutic drug candidates - and shorten discovery times. - R&D Expenditure 2007
-
Worldwide: 6.4 billion US $
- Employees in the Pharmaceuticals Division
-
(12-31-2007)
Worldwide: 98,200
In Germany: 1,900
(All data based on corporate information, as of: 02/2008)
Unless indicated otherwise, data and keywords refer to the company's human therapeutics sector in Germany and to that of its international Group worldwide.
Unless indicated otherwise, data and keywords refer to the company's human therapeutics sector in Germany and to that of its international Group worldwide.
Suggest page
Print page
Bookmark page